Cytek Biosciences announced preliminary Q4 2025 revenue of approximately $62 million, representing 8% year-over-year growth and 19% sequential growth. Full year 2025 revenue is expected to be approximately $201 million. The company highlighted strong growth in Services, Reagents, and Asia Pacific instrument revenue, along with improved instrument sales in the US and EMEA regions, particularly a return to positive growth in EMEA.

Cytek Biosciences was recognized by TIME and Statista as one of America's top-performing publicly listed companies, highlighting its exceptional growth, financial stability, and innovative cell analysis solutions.

Cytek Biosciences' Muse Micro cell analyzer won the 2025 BioTech Breakthrough Award for Drug Discovery Solution of the Year, highlighting its innovative approach to making cell analysis more accessible and cost-effective for laboratories.

Cytek Biosciences is launching a two-part research support initiative to make cell analysis more accessible, including awarding a flow cytometer and planning a research grant program in collaboration with ISAC to support scientific research globally.

Cytek Biosciences relocates and expands its European headquarters in Amsterdam, increasing its facility footprint by over 40% and establishing a dedicated customer service and training center to strengthen its presence in the EMEA region.

Cytek Biosciences will showcase its advanced cell analysis solutions at ESCCA and ICCS conferences, highlighting its Full Spectrum Profiling technology and its potential to transform cell biology research through high-parameter spectral flow cytometry.

MDxHealth appointed Michael Holder to its Board of Directors as Audit Committee Chair, replacing Regine Slagmulder. CFO Ron Kalfus is resigning, with Scott McMahan assuming interim CFO responsibilities.

Cytek Biosciences has launched the Cytek Aurora™ Evo, a new full spectrum flow cytometer that improves on its flagship Cytek Aurora system. The new system offers high-throughput and automation capabilities to meet the demands of modern research.

Cytek Biosciences, a leader in cell analysis solutions, will showcase its patented Full Spectrum Profiling technology at two prominent industry events, CYTO 2025 and IMMUNOLOGY2025. The technology is designed to streamline workflows, accelerate discoveries, and enhance efficiency in flow cytometry research and clinical studies.

The global flow cytometry market is expected to grow from $6.38 billion in 2024 to $12.66 billion by 2034, driven by technological advancements and expanding applications. The USA, Germany, China, and India are expected to see strong growth in this market.

Cytek Biosciences, a leading cell analysis solutions company, has been named the "Overall BioTech Company of the Year" in the 2024 BioTech Breakthrough Awards program, recognizing its pioneering work in spectral flow cytometry and advancements in cell analysis tools.

Cytek Biosciences has introduced an Enhanced Small Particle (ESP) Detection Option for its Cytek Aurora CS system, enabling researchers to study and sort particles as small as 70 nm, opening new possibilities for breakthroughs in drug delivery, cell therapy, and other fields.